PI-103

PI-103は、強力な、細胞透過性、ATP競争的クラスI PI3K阻害剤で、DNA-PK、 p110α、 mTORC1、 PI3-KC2β、 p110δ、 mTORC2、 p110β、p110γ に作用すると、IC50 がそれぞれ 2 nM、 8 nM、 20 nM、26 nM、 48 nM、 83 nM、 88 nM 、150 nMになる。

価格 在庫  
USD 168 あり
USD 185 あり
USD 340 あり
USD 466 あり

PI-103 化学構造
分子量: 348.36

高品質保証

カスタマーフィードバック(4)

Quality Control & MSDS

製品説明

  • Compare PI3K Inhibitors
    PI3K製品生物活性の比較
  • 研究分野
  • PI-103のメカニズム

製品の説明

生物活性

製品説明 PI-103は、強力な、細胞透過性、ATP競争的クラスI PI3K阻害剤で、DNA-PK、 p110α、 mTORC1、 PI3-KC2β、 p110δ、 mTORC2、 p110β、p110γ に作用すると、IC50 がそれぞれ 2 nM、 8 nM、 20 nM、26 nM、 48 nM、 83 nM、 88 nM 、150 nMになる。
ターゲット p110α p110β p110δ p110γ mTOR DNA-PK
IC50 2 nM 3 nM 3 nM 15 nM 30 nM 23 nM [3]
In vitro試験 PI-103 potently inhibits both the rapamycin-sensitive (mTORC1) and rapamycin-insensitive (mTORC2) complexes of the protein kinase mTOR. [1] PI-103 inhibits constitutive and growth factor-induced PI3K/Akt, as well as mTORC1 activation. [2] In blast cells, PI-103 inhibits leukemic proliferation, the clonogenicity of leukemic progenitors and induces mitochondrial apoptosis, especially in the compartment containing leukemic stem cells. PI-103 inhibits p110α >200-fold more potently than p110β. PI-103 also potently blocks production of PI(3,4)P2 and PIP3 in adipocytes and PIP3 in myotubes. [2] PI-103 inhibits phosphorylation of Akt with an IC95 100-fold lower than that for LY294002. Strikingly, PI-103 completely protects animals from insulin-stimulated decline in blood glucose. PI-103 has additive proapoptotic effects with etoposide in blast cells and in immature leukemic cells. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
SK-N-BE NX6yfmZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vtU|AuQCEQvF2= NV6zSJRnOjRxNEivO|IhcA>? M2jsSolv\HWlZYOgeIlu\S1iYX7kJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnubIljcXSrb36gc44hVkJiY3XscEBoem:5dHi= NYnQUZc4OjZ{MkS2PFE>
SH-SY5Y MonPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXGwMVgh|ryP MofNNlQwPDhxN{KgbC=> M{jEVIlv\HWlZYOgeIlu\S1iYX7kJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnubIljcXSrb36gc44hVkJiY3XscEBoem:5dHi= NG\Oe2szPjJ{NE[4NS=>
SH-SY5Y  MUTBdI9xfG:|aYOgRZN{[Xl? MXyxJO69VQ>? NWjoUpZbOC53LUK0JIg> NV;sPYFQe2Wwc3n0bZpmeyCwZYXyc4Jt[XO2b33hJINmdGy|IITvJIRwgG:{dXLpZ4lvNWmwZIXj[YQh[XCxcITvd4l{ NHXoXYszPjJ{NE[4NS=>
G 35 SC M3jvSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3K5WVAvODVvMkCg{txO MW[yOE84OiCq NX\URZFMTE2VTx?= MVLpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 NEjnbHIzPjF{MUK1NS=>
G 38 SC Mni3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrKe4ZDOC5yNT2yNEDPxE1? MlyyNlQwPzJiaB?= MYPEUXNQ NImzR4VqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfGy7 M321WlI3OTJzMkWx
G 40 SC NWLxPYpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TPZVAvODVvMkCg{txO NVrWUHJVOjRxN{KgbC=> M1r0cGROW09? MXnpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 NH;Z[2gzPjF{MUK1NS=>
G 35 DC MnPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33FXVAvODVvMkCg{txO NF7odnYzPC95MjDo NE\QRo9FVVOR MXzpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 M3;OV|I3OTJzMkWx
G 38 DC MorMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUX4emJWOC5yNT2yNEDPxE1? NHLVZnkzPC95MjDo MYjEUXNQ MUTpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 M1S4flI3OTJzMkWx
G 40 DC M1O0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1iwPVAvODVvMkCg{txO MUmyOE84OiCq MmDySG1UVw>? MX\pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 MVWyOlEzOTJ3MR?=
RD NH3PXYNCeG:ydH;zbZMhSXO|YYm= MoTuNU8yNjVxMjFOwG0> MYK3NkBp NVzBOnBRcW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDHRW5VPjF? MYmyOVc1QTN5OB?=
TE381.T NYPoNGw3SXCxcITvd4l{KEG|c3H5 MU[xM|EvPS9{IN88US=> M4LzS|czKGh? MX3pcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKEeDTmS2NS=> NX7YW|FvOjV5NEmzO|g>
RMS13 MUDBdI9xfG:|aYOgRZN{[Xl? NH7aXHcyNzFwNT:yJO69VQ>? M1PNdVczKGh? NEDmc|NqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFfBUnQ3OQ>? M2LlZlI2PzR7M{e4
RH30  MoDnRZBweHSxc3nzJGF{e2G7 M2DN[FEwOS53L{Kg{txO NGjDXYM4OiCq MXTpcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKEeDTmS2NS=> NUDYWnBuOjV5NEmzO|g>
VJ M2XFOGFxd3C2b4Ppd{BCe3OjeR?= NUGxTXJqOS9zLkWvNkDPxE1? NHjMcoM4OiCq MUXpcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKEeDTmS2NS=> MYiyOVc1QTN5OB?=
HS578T NHLXZoZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Ml7CNE0{KM7:TR?= M1\XUlczKGh? M17afYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? M1roflI2PzJzNEG5
BT549 NHu3b29E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NEDJ[24xNTNizszN NFLqb2E4OiCq MnPsbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? M1rCclI2PzJzNEG5
MDA-MB-231 MmWxR4VtdCCYaXHibYxqfHliQYPzZZk> MkfSNE0{KM7:TR?= NE[3NYw4OiCq NH;qTYVqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 Ml3lNlU4OjF2MUm=
MDA-MB-468 MmXER4VtdCCYaXHibYxqfHliQYPzZZk> MkT0NE0{KM7:TR?= M1zLRlczKGh? Ml7vbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NHrISlkzPTd{MUSxPS=>
MDA-MB-436 MYfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M4[4UVAuOyEQvF2= MV:3NkBp NXz6V5V7cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M3;mZlI2PzJzNEG5
SUM149PT MXPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MnmxNE0{KM7:TR?= NYm3UpJVPzJiaB?= MmTkbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MnHSNlU4OjF2MUm=
MDA-MB-468 NGPGbZBHfW6ldHnvckBCe3OjeR?= NGHPXWgxNjBzLUGwJO69VQ>? MmH1NlQhcA>? NGXr[XVld3ewcnXneYxifGW|IITo[UBt\X[nbIOgc4Yh|rJvVILDVFEtKGNvTYnjJIFv\CCleXPsbY4hTSCycn;0[Ylve8Li NWTtdpVjOjV5MkG0NVk>
MDA-MB-231 MXjGeY5kfGmxbjDBd5NigQ>? NXn6WWNPOC5yMT2xNEDPxE1? M3XRXVI1KGh? NInWW4pld3ewcnXneYxifGW|IITo[UBt\X[nbIOgc4Yh|rJvVILDVFEtKGNvTYnjJIFv\CCleXPsbY4hTSCycn;0[Ylve8Li NWWyPFhSOjV5MkG0NVk>
HS578T MVXGeY5kfGmxbjDBd5NigQ>? NVXDNHQ3OC5yMT2xNEDPxE1? NWryOHRyOjRiaB?= NUX1[Go{\G:5boLl[5Vt[XSnczD0bIUhdGW4ZXzzJI9nKM7{LWTyR3AyNCClLV35Z{BidmRiY4njcIlvKEVicILveIVqdnQEoB?= MlnRNlU4OjF2MUm=
SW872 MmToSpVv[3Srb36gRZN{[Xl? MUiwMlAyNTBwNTFOwG0> MVGyOEBp NEXPZo1z\WS3Y3XzJGFMXCCyaH;zdIhwenmuYYTpc44hMHCDS2SpJIFv\CB2RVLQNUBxcG:|cHjvdplt[XSrb36gLJA1TUKSMTmgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYNCpC=> Mlv5NlQ3QTV4M{K=
SW982 MV7GeY5kfGmxbjDBd5NigQ>? MmfDNE4xOS1yLkWg{txO M1TzSFI1KGh? MnnQdoVlfWOnczDBT3QheGixc4Doc5J6dGG2aX;uJEhxSUuWKTDhcoQhPEWEUEGgdIhwe3Cqb4L5cIF1cW:wIDjwOGVDWDFrIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{wrC= M1WwW|I1Pjl3NkOy
SW872 M13DZWFxd3C2b4Ppd{BCe3OjeR?= MWqwMlAyNTBwNTFOwG0> NWjH[I9YPDhiaB?= MWnpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 M2C1UVI1Pjl3NkOy
SW982 NGnHbHJCeG:ydH;zbZMhSXO|YYm= NHfVOogxNjBzLUCuOUDPxE1? M4j1T|Q5KGh? NFnZRVVqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 Mm\PNlQ3QTV4M{K=
AGS HG NVm4SW5zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;kc2lEPTB;MD62PEDDuSByLkCzNUDPxE1? NXX2T5NSOjR3OUe0O|g>
AGS LG MmnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHWfJpKSzVyPUCuNFUhyrFiMD6wNFEh|ryP MX:yOFU6PzR5OB?=
HGC27 HG MkHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjrZnBKSzVyPUCuN|ghyrFiMD6wNlIh|ryP NFvIbHIzPDV7N{S3PC=>
HGC27 LG MmXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfSTJFNUUN3ME2wMlAzKMLzIECuNFA1KM7:TR?= MnnRNlQ2QTd2N{i=
MKN45 HG MoSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;IcmlEPTB;MT6wNUDDuSByLkC1NUDPxE1? M32wR|I1PTl5NEe4
MKN45 LG NGTjUVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXi1W4RWUUN3ME2wMlg4KMLzIECuNFMxKM7:TR?= NEi0Z3AzPDV7N{S3PC=>
NUGC4 HG MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfPUIdvUUN3ME2xOE4xKMLzIEOuPVE{KM7:TR?= NUm5OGwzOjR3OUe0O|g>
NUGC4 LG NUfqN29VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nBbmlEPTB;MUSuNEDDuSB3LkOyNUDPxE1? NIL4V5EzPDV7N{S3PC=>
A549 Mn7oSpVv[3Srb36gRZN{[Xl? M3ixOVAvOjVxMD61M|Eh|ryP MXyyOEBp NVTy[JlqcW6qaXLpeJMhSWu2IIDoc5NxcG:{eXzheIlwdiC|bHnnbJRtgQ>? Mk[1NlQ{PTF2MkW=
H460 MnLJSpVv[3Srb36gRZN{[Xl? NF\4cW8xNjJ3L{CuOU8yKM7:TR?= NWmwXmVGOjRiaB?= MYXpcohq[mm2czDBb5QheGixc4Doc5J6dGG2aX;uJJNtcWeqdHz5 MWqyOFM2OTR{NR?=
H661 MX3GeY5kfGmxbjDBd5NigQ>? MYCwMlI2NzBwNT:xJO69VQ>? MkT2NlQhcA>? NInyOVdqdmirYnn0d{BCc3RicHjvd5Bpd3K7bHH0bY9vKHOrZ37p[olk[W62bIm= NXqyfHBSOjR|NUG0NlU>
SAS NFv4[GlHfW6ldHnvckBCe3OjeR?= MVSwMlI2NzBwNT:xJO69VQ>? NIHzepUzPCCq NWXvb2VGcW6qaXLpeJMhSWu2IIDoc5NxcG:{eXzheIlwdiC|aXfubYZq[2GwdHz5 MknCNlQ{PTF2MkW=
UT5 NEP3[2JHfW6ldHnvckBCe3OjeR?= M3fHTlAvOjVxMD61M|Eh|ryP M3LrTFI1KGh? NEnTZZVqdmirYnn0d{BCc3RicHjvd5Bpd3K7bHH0bY9vKHOrZ37p[olk[W62bIm= MXuyOFM2OTR{NR?=
FaDu NV73dVJVTnWwY4Tpc44hSXO|YYm= NXLwcYhnOC5{NT:wMlUwOSEQvF2= MUOyOEBp NVrDNGtqcW6qaXLpeJMhSWu2IIDoc5NxcG:{eXzheIlwdiC|aXfubYZq[2GwdHz5 MVGyOFM2OTR{NR?=
RD M{\mTmFxd3C2b4Ppd{BCe3OjeR?= M2WxcFEwOS53L{Kg{txO NXPLSJVXPzJiaB?= MonnSG1UVw>? NFe1fmpqdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIGXPNVI3 NXvyT3h2OjN4OES5NlU>
TE671 M{W0bWFxd3C2b4Ppd{BCe3OjeR?= MlmzNU8yNjVxMjFOwG0> MUW3NkBp MXrEUXNQ NG\SS|hqdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIGXPNVI3 MWCyN|Y5PDl{NR?=
RH30  MWfBdI9xfG:|aYOgRZN{[Xl? MnH6NU8yNjVxMjFOwG0> NWPB[Fk3PzJiaB?= NFGyeYFFVVOR NFrudZBqdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIGXPNVI3 NVHkSmY3OjN4OES5NlU>
RMS13 MXrBdI9xfG:|aYOgRZN{[Xl? NX:xdI9TOS9zLkWvNkDPxE1? NHLReHM4OiCq NYf6cmhbTE2VTx?= M4Llcolv\HWlZYOgZ4F{eGG|ZT3k[ZBmdmSnboSgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiVV:xNlY> NFznfIczOzZ6NEmyOS=>
SUM149PT M{DXbmNmdGxiVnnhZoltcXS7IFHzd4F6 MnHqNE4{KM7:TR?= M2HndlczKGh? NH7NeIRmdmijbnPld{BkgXSxdH;4bYMh\W[oZXP0d{Bw\iCSSUPLM2FMXCCyYYToe4F6KGmwaHnibZRwenN? MWqyN|YxOTB5NB?=
MDA-MB-468 M{LZNWNmdGxiVnnhZoltcXS7IFHzd4F6 M1TnVlAvOyEQvF2= MYm3NkBp NIHWT5RmdmijbnPld{BkgXSxdH;4bYMh\W[oZXP0d{Bw\iCSSUPLM2FMXCCyYYToe4F6KGmwaHnibZRwenN? M4W3cVI{PjBzMEe0
MDA-MB-231 MYjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NIr6bmkxNjNizszN Mlu4O|IhcA>? NFrpbWlmdmijbnPld{BkgXSxdH;4bYMh\W[oZXP0d{Bw\iCSSUPLM2FMXCCyYYToe4F6KGmwaHnibZRwenN? MlnUNlM3ODFyN{S=
SY5Y MYfGeY5kfGmxbjDBd5NigQ>? NIXCS3cyNjVxMj61M|Uh|ryP NFvaRZAzPCCq MWXpcoR2[2W|IFexxsBk\WyuLXP5Z4xmKGG{cnXzeEBidmRiYYDvdJRwe2m| M2jRNFI{Ozd6M{Sx
SKNBE(2c) MYrGeY5kfGmxbjDBd5NigQ>? MX[xMlUwOi53L{Wg{txO NXPKcm5EOjRiaB?= M1;iWYlv\HWlZYOgS|HDqGOnbHytZ5lkdGViYYLy[ZN1KGGwZDDhdI9xfG:|aYO= NFHVWW0zOzN5OEO0NS=>
RD NF\hRpdCeG:ydH;zbZMhSXO|YYm= NVHCbY92OyEEtV2= MlTzNVIhcA>? MljiSG1UVw>? MUDz[Y5{cXSrenXzJHJFKGOnbHzzJJRwKESRWD3pcoR2[2WmIHHwc5B1d3Orcx?= NH;xbmIzOzNyMEiwPS=>
TP5014 MWfBdI9xfG:|aYOgRZN{[Xl? NHP0Z|I{KML3TR?= NInBRlgyOiCq MULEUXNQ NY\LNlVMe2Wwc3n0bZpmeyCURDDj[YxteyC2bzDEU3gucW6mdXPl[EBieG:ydH;zbZM> MXWyN|MxODhyOR?=
HT1080 M1z3WWFxd3C2b4Ppd{BCe3OjeR?= NUHENFFkOyEEtV2= NXjxe49xOTJiaB?= NH\YWZFFVVOR NXe5OYZ{e2Wwc3n0bZpmeyCURDDj[YxteyC2bzDEU3gucW6mdXPl[EBieG:ydH;zbZM> MlnqNlM{ODB6MEm=
A549 NFu0fnRHfW6ldHnvckBCe3OjeR?= NU\ZdmhtOC1|LkOg{txO M2fBc|czKGh? MYXpcoR2[2W|IHPvcZBt\XSnIHTve45z\We3bHH0bY9vKG:oIIDBT3Q> NFfhc4QzOzJ3OUW5NS=>
HCC827 MUfGeY5kfGmxbjDBd5NigQ>? M3;3VVAuOy5|IN88US=> MY[3NkBp MkWxbY5lfWOnczDjc41xdGW2ZTDkc5dvemWpdXzheIlwdiCxZjDwRWtV NFi2dFgzOzJ3OUW5NS=>
H3122 Ml;QSpVv[3Srb36gRZN{[Xl? MWWwMVMvOyEQvF2= NXTh[lBYPzJiaB?= M33vfYlv\HWlZYOgZ49ueGyndHWg[I94dnKnZ4XsZZRqd25ib3[gdGFMXA>? NX6ye25QOjN{NUm1PVE>
TALL-1 MmXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;SNgKBkc7:TR?= NYXTWoRRPyCm MonY[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 M{X1WVI{ODN6Mkez
HPB-ALL MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFv5fHEy6oDLzszN MYi3JIQ> NUfDSVdt\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 MWKyN|A{QDJ5Mx?=
DND41 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTOOIF5OeLCid88US=> M4SyTFch\A>? M1nCWoRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? NULOToJxOjNyM{iyO|M>
SUP-T1 NXyxRoRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYqx5qCK|ryP NG[x[Ws4KGR? NXHMfIxv\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 MnXINlMxOzh{N{O=
PEER NIXmd3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{ixRVHjiIoQvF2= NITobZE4KGR? NIjKT3Bl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? NVv5OGFEOjNyM{iyO|M>
ALL-SIL NFztTXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXmx5qCK|ryP NUPQW3R2PyCm NVr6bGR3\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 NHzsWo4zOzB|OEK3Ny=>
KE37 M{P6OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnHNgKBkc7:TR?= M37zXVch\A>? NIrmXIRl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? M3HJSlI{ODN6Mkez
Karpas-45 M2qwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvHNgKBkc7:TR?= NHP2U5c4KGR? NWqy[pky\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 NYX6NJFWOjNyM{iyO|M>
RPMI-8402 NFS4bW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXex5qCK|ryP M3:zS|ch\A>? M2rT[IRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? M1\kSVI{ODN6Mkez
Jurkat MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXWx5qCK|ryP MYi3JIQ> NYD3V4N4\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 MUWyN|A{QDJ5Mx?=
MOLT-4 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWWx5qCK|ryP NVLzUpBsPyCm M4TzS4Rm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? NGr2VWEzOzB|OEK3Ny=>
PF-382 MknzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;zTYVIOeLCid88US=> MWS3JIQ> NYjZbXd2\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 Ml23NlMxOzh{N{O=
CCRF-CEM MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2myfFHjiIoQvF2= NEDJV5k4KGR? NHqwT3hl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? M4r4eVI{ODN6Mkez
LOUCY MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrKfYYy6oDLzszN MlnjO{Bl M3\T[oRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? MYCyN|A{QDJ5Mx?=
MOLT-16 M1q4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37IVVHjiIoQvF2= NF;nVGE4KGR? Mlfo[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 NWDlRlFiOjNyM{iyO|M>
MM1S MorHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\vNE0zKM7:TR?= NHXhcVEzPCCq MWXJR|UxRTBwNTFOwG0> NFntdYszOjh{OUKzOC=>
NCI-H929 MofHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHWNE0zKM7:TR?= MorTNlQhcA>? Ml25TWM2OD1yLkK1JO69VQ>? MX[yNlgzQTJ|NB?=
KMS12-BM  M{HyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPlS4cxNTJizszN MWqyOEBp Ml2xTWM2OO,:nkKg{txO NWD1ZoNKOjJ6MkmyN|Q>
MDA-MB-436 NGrkb2VHfW6ldHnvckBCe3OjeR?= NEHFSHoyKM7:TR?= MmjvNlQhcA>? NX\JSWcyemWmdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHLWC=> M4[2[|IzPDh6NUmw
SUM149PT NUHDNVFnTnWwY4Tpc44hSXO|YYm= M3XwSlEh|ryP MmnVNlQhcA>? NUe1e|lPemWmdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHLWC=> NV;iZm44OjJ2OEi1PVA>
SUM1315MO2 MW\GeY5kfGmxbjDBd5NigQ>? NVLZZ2xkOSEQvF2= MlzYNlQhcA>? M1iwTZJm\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCDS2S= NE\nVpYzOjR6OEW5NC=>
HCC1937 MVnGeY5kfGmxbjDBd5NigQ>? MYWxJO69VQ>? M2nq[FI1KGh? NVTuTpZ2emWmdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHLWC=> MXuyNlQ5QDV7MB?=
HCC827 MlfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjHNE0{KM7:TR?= M2LuXVczKGh? Mm\aTWM2OD1yLkOg{txO NFvjdHYzOTJ{MES3OC=>
PC-9  M3i3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3xNE0{KM7:TR?= NFnmNZE4OiCq NFv2V4tKSzVyPUCuPEDPxE1? MnjoNlEzOjB2N{S=
LN229 NE\lW4ZHfW6ldHnvckBCe3OjeR?= NX7tXVdLOSEQvF2= M2[xXFQ5KGh? NGS4XlJqdmS3Y3XzJIF2fG:yaHHnc5NwdWViZn;ycYF1cW:w M3vGRlIyODZ{OUmz
U87 NFrzfHJHfW6ldHnvckBCe3OjeR?= MWOxJO69VQ>? NV3FbG9SPDhiaB?= MlPKbY5lfWOnczDheZRweGijZ3;zc41mKG[xcn3heIlwdg>? MWmyNVA3Ojl7Mx?=
U373 M{i2N2Z2dmO2aX;uJGF{e2G7 MXSxJO69VQ>? M1vY[VQ5KGh? M1fOeolv\HWlZYOgZZV1d3CqYXfvd49u\SCob4LtZZRqd25? NUH3T25QOjFyNkK5PVM>
SF767 NEXlWnBHfW6ldHnvckBCe3OjeR?= NWrYUolUOSEQvF2= NUjyeG1EPDhiaB?= M3rNO4lv\HWlZYOgZZV1d3CqYXfvd49u\SCob4LtZZRqd25? NVHJTVZoOjFyNkK5PVM>
Mel-Juso M4rkcGNmdGxiVnnhZoltcXS7IFHzd4F6 MlmyNE4xOeLCk{Gw5qCK|ryP M1TQPVczKGh? MVfpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MnPNNlExPDh5OEW=
518A2  NXLvNFJjS2WubDDWbYFjcWyrdImgRZN{[Xl? NU\FUXdnOC5yMfMAl|Ex6oDLzszN NWn4OngxPzJiaB?= NYS5VHh7cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= Mm\UNlExPDh5OEW=
Mel-Juso  M2r6fWZ2dmO2aX;uJGF{e2G7 NGi4e3kxNjByMfMAl|HjiIoQvF2= NHi2ZoozPCCq M{f6[5N2eHC{ZYPz[ZMheGixc4Doc5J6dGG2aX;uJI9nKHCqb4PwbIF1cWS7bDDpco9{cXSxbDCzMYtqdmG|ZTDkc5dve3S{ZXHtJJRiemendIO= MWiyNVA1QDd6NR?=
518A2 MVTGeY5kfGmxbjDBd5NigQ>? M3XXOlAvODBz4pETNgKBkc7:TR?= NX\EVVZCOjRiaB?= M4L1O5N2eHC{ZYPz[ZMheGixc4Doc5J6dGG2aX;uJI9nKHCqb4PwbIF1cWS7bDDpco9{cXSxbDCzMYtqdmG|ZTDkc5dve3S{ZXHtJJRiemendIO= NGTZZVgzOTB2OEe4OS=>
PC3  NUHD[45ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnK2NlRp Mk\SS2k2OMLiPTCxNFAhdk1? NWfY[ZBDOjB3NUGwOlE>
U87MG MoK5SpVv[3Srb36gRZN{[Xl? MVGwMlEuOSEQvF2= NUjv[HprOjUkgJnoxsA> MorhSG1UVw>? MUjpcohq[mm2czDQTVNMNW2nZHnheIVlKHOrZ37hcIlv\w>? MoHLNVk3OzN4OEO=
U138MG NWS4b405TnWwY4Tpc44hSXO|YYm= MofMNE4yNTFizszN M2nCfFI16oDLaNMg NHT4VG9FVVOR NWTVR2lIcW6qaXLpeJMhWEl|Sz3t[YRq[XSnZDDzbYdv[Wyrbne= NFzpe|MyQTZ|M{[4Ny=>
U118MG NIewVIpHfW6ldHnvckBCe3OjeR?= MlTuNE4yNTFizszN M3yzdlI16oDLaNMg M{jJT2ROW09? M3OzbIlvcGmkaYTzJHBKO0tvbXXkbYF1\WRic3nncoFtcW6p NV2wSlVZOTl4M{O2PFM>
U87MG MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmC0TWM2OD1yLkG0JO69VQ>? M4X4RVE6PTh2MkK3
IGROV-1 M2DXdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEC4OIFKSzVyPUCuNFYh|ryP MX:xPVU5PDJ{Nx?=
DETROIT562 M{XVe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXqTWM2OD1yLkGzJO69VQ>? MYKxPVU5PDJ{Nx?=
PC3  NV63UmxnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTBwMUCg{txO MkHxNVk2QDR{Mke=
SKOV-3 NFLKZoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwMUKg{txO MUGxPVU5PDJ{Nx?=
HUVEC NVnK[nJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHKO2dKSzVyPUCuNFgh|ryP NEPpZpIyQTV6NEKyOy=>
UCH-1  NGfHUm1HfW6ldHnvckBCe3OjeR?= NXnhW21DOC13IN88US=> NHvS[WVqdmirYnn0d{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIHLveIghSUuWIHHu[EBuXE:UIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NWLwV4JGOTl3Mki0OFE>
UCH-1  M{fMd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYGwMlAyNTFyIN88US=> Mn;yOkBl Mme0bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCmb4PlJIRmeGWwZHXueIx6 NEXnOmoyQTV{OES0NS=>
UCH-1  MlXsRZBweHSxc3nzJGF{e2G7 M3XIPFAvOS1zMDFOwG0> MYSyOEBp NYC4NVh6TE2VTx?= M1vaOYlv\HWlZYOgZZBweHSxc3nz MVGxPVUzQDR2MR?=

... Click to View More Cell Line Experimental Data

In vivo試験 When tumors reach 50-100 mm3, animals are randomized and treated with vehicle or PI-103. PI-103 exhibits significant activity, decreasing average tumor size by 4-fold after 18 days. [2] Mice treated with PI-103 have no obvious signs of toxicity premorbidly (based on body weight, food and water intake, activity, and general exam) or at necropsy. Treated tumors display decreased levels of phosphorylated Akt and S6, consistent with blockade of p110α and mTOR. PI-103 treatment is cytostatic to glioma xenografts. [2]
臨床試験
特集 The first potent, synthetic mTOR inhibitor.

プロトコル (参考用のみ)

キナーゼアッセイ: [3]

Enzyme Assays Phosphatidylinositide 3-kinase inhibitory activity was determined using a scintillation proximity assay in the presence of 1 μmol/L ATP. Inhibition of mTOR protein kinase was determined using a TR-FRET-based LanthaScreen method from Invitrogen. Compounds were assayed at a maximum concentration of 10 μmol/L in the presence of 1 μmol/L ATP, and IC50 values were determined using GraphPad Prism software.

細胞アッセイ: [2]

細胞株 U87MG cells
濃度 0.5 μM
反応時間 24 hours
実験の流れ U87MG cells are treated with PI-103 for 24 hours. Cell death is quantified by colorimetric determination of LDH activity using a cytotoxicity detection kit. Percentage of cell death (mean of three 12-well plates per experimental point) is calculated [(experimental value- low control)/(high control -low control) × 100], where the low-control cells are DMSO treated and high-control cells are Triton treated (1% Triton X-100, 30 min, 37 °

動物実験: [2]

動物モデル 6- to 12-week-old Balbc nu/nu mice bearing U87MG:ΔEGFR cells
製剤 50% DMSO
投薬量 5 mg/kg
投与方法 Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download PI-103 SDF
分子量 348.36
化学式

C19H16N4O3

CAS No. 371935-74-9
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 24 mg/mL (68.89 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 Phenol, 3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]-

カスタマーフィードバック (4)


Click to enlarge
Rating
Source Mol Carcinog, 2012, 52, 667-75 . PI-103 purchased from Selleck
Method Western blot
Cell Lines MCF7 cells
Concentrations 0-1 μM
Incubation Time 24 h
Results In BRCA1-KD MCF7 cells, treatment of PI-103, a PI3K/mTOR inhibitor, abolished phosphorylation of AKT and its substrate GSK3b, in a dose dependent manner (Figure A). Treatment of PI-103 reduced the phosphorylation of AKT in all BRCA1 mutant breast cancer cells tested (Figure B). Phosphorylations of downstream targets of AKT, such as phospho-GSK3b (S9) and phospho-BAD(S112) were also reduced by PI-103 treatment. Phosphorylation of mTOR at S2448, which is also known to be phosphorylated by AKT, was also reduced by PI-103 resulting in reduced phosphorylation of S6 ribosomal protein at S235/236 (Figure B). The effect of PI-103 was much more potent than LY294002 in MDA-MB-436 cells (Figure B)

Click to enlarge
Rating
Source Mol Carcinog, 2012, ahead of print. PI-103 purchased from Selleck
Method MTT assay
Cell Lines MCF7 cells
Concentrations 0.01-1 μM
Incubation Time 48 h
Results Knockdown of BRCA1 can sensitize the MCF7 cells to Perifosine in a dose-dependent manner (Figure A). BRCA1-KD also sensitizes the MCF7 cells to dual PI3K/mTOR inhibitors, such as PI-103 or BEZ235 (Figure B, D). Another inhibitor, PIK-75 which specifically inhibits PI3Ka and PI3Kg, but not mTOR, also showed similar effects on proliferation of BRCA1-KD MCF7 cells (Figure C).

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. PI-103 purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-1 nM
Incubation Time 24 h
Results PI-103 treatment resulted in a reduction of Akt phosphorylation in Breast cancer cells.

Click to enlarge
Rating
Source Saraswati Sukumar of Johns Hopkins University School of Medicine, PI-103 purchased from Selleck
Method Western blot
Cell Lines T47D cells
Concentrations
Incubation Time 1 h
Results PI-103 treatment resulted in a reduction of Akt phosphorylation in T47D cells.

文献中の引用 (21)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related PI3K 阻害剤

  • GDC-0032

    GDC-0032 is a potent, next-generation PI3K inhibitor targeting PI3K alpha.

    Features:A beta isoform-sparing PI3K inhibitor.

  • Pilaralisib (XL147)

    Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.

  • GNE-317

    GNE-317 is a potent, brain-penetrant PI3K inhibitor.

  • PI-3065

    PI-3065 is a selective p110δ inhibitor with IC50 of 15 nM, >70-fold selectivity over other PI3K family members.

  • LY294002

    LY294002は、p110α、p110δとp110βのPI3K阻害剤で、IC50 がそれぞれ 0.5 μM、0.57 μM、0.97 μMです。

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA) は選択の自噬とリン酸イノシトール3キナーゼ(キナーゼ)阻害剤、Vps34 と PI3Kγ に作用する時、 IC50 がそれぞれ 25 nM と 60 nM になる。自動食物胞の形成を妨害すること。

  • CAL-101 (Idelalisib, GS-1101)

    CAL-101 (Idelalisib, GS-1101)は、2.5nMのIC50によるp110δの選択的なPI3KクラスI阻害剤です。

  • Wortmannin

    ワートマニンはミオシン軽鎖キナーゼ(MLCK)のマルチターゲットの阻害剤、IC50がぞれぞれ0.17μMと3nMになる。自動食物胞の形成を妨害すること。

  • BEZ235 (NVP-BEZ235, Dactolisib)

    BEZ235 (NVP-BEZ235, Dactolisib)は競争性的なPI3K、mTOR 阻害剤、 p110α, p110γ, p110δ と p110β を作用すると、 IC50 がぞれぞれ 4 nM, 5 nM, 7 nM と 75 nMになる.

  • BKM120 (NVP-BKM120, Buparlisib)

    BKM120 (NVP-BKM120, Buparlisib)は、p110α、p110β、p110δとp110γの選択的なPI3K阻害剤で、IC50 がそれぞれ 52-99 nM、166 nM、 116 nM、 262 nMです。

最近チェックしたアイテム

Tags: PI-103を買う | PI-103供給者 | PI-103を購入する | PI-103費用 | PI-103生産者 | オーダーPI-103 | PI-103代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ